Ying Yuan, Ph.D. - Publications

Affiliations: 
2005 University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Biostatistics Biology

123 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Statistics in Medicine. PMID 35098585 DOI: 10.1002/sim.9337  0.322
2021 Mu R, Xu J, Tang RS, Kopetz S, Yuan Y. A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. Statistics in Medicine. PMID 34730248 DOI: 10.1002/sim.9242  0.302
2021 Lin R, Thall PF, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Analysis. 16: 179-202. PMID 34267857 DOI: 10.1214/20-ba1205  0.318
2021 Jiang L, Li R, Yan F, Yap TA, Yuan Y. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemporary Clinical Trials. 106338. PMID 33711459 DOI: 10.1016/j.cct.2021.106338  0.319
2021 Shi H, Cao J, Yuan Y, Lin R. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials. Statistics in Medicine. PMID 33650708 DOI: 10.1002/sim.8922  0.325
2020 Atkins JT, George GC, Hess K, Marcelo-Lewis KL, Yuan Y, Borthakur G, Khozin S, LoRusso P, Hong DS. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. British Journal of Cancer. PMID 32868897 DOI: 10.1038/S41416-020-01033-X  0.344
2020 Abi Jaoude J, Kouzy R, Minsky BD, Fuller CD, Yuan Y, Do KA, Taniguchi CM, Ludmir EB. Sponsor-Involved Statistical Analyses in Phase III Cancer Clinical Trials. International Journal of Cancer. PMID 32621758 DOI: 10.1002/Ijc.33180  0.507
2020 Zhou H, Chen C, Sun L, Yuan Y. Bayesian optimal phase II clinical trial design with time-to-event endpoint. Pharmaceutical Statistics. PMID 32524679 DOI: 10.1002/Pst.2030  0.394
2020 Pan H, Cheng C, Yuan Y. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction. Pharmaceutical Statistics. PMID 32248647 DOI: 10.1002/Pst.2013  0.677
2020 Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemporary Clinical Trials. 105972. PMID 32151751 DOI: 10.1016/J.Cct.2020.105972  0.681
2020 Li Y, Yuan Y. PA-CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials. Biometrics. PMID 31950483 DOI: 10.1111/Biom.13217  0.37
2020 Lin R, Thall PF, Yuan Y. A Phase I–II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes Bayesian Analysis. DOI: 10.1214/20-Ba1205  0.371
2020 Gunn GB, Ferrarotto R, Johnson FM, Bell D, Cardoso R, Johnson JM, Rubin ML, Yuan Y, Frank SJ, Fuller CD, Rosenthal DI, Kupferman ME, Goepfert R, Hessel AC, Hutcheson KA, et al. Prospective, longitudinal digital activity monitoring before and after treatment of low-risk oropharyngeal squamous cell carcinoma: A feasibility study. Journal of Clinical Oncology. 38: 6578-6578. DOI: 10.1200/Jco.2020.38.15_Suppl.6578  0.417
2020 Majd N, Lin HY, Yuan Y, Alfaro-Munoz K, Hunter K, Heimberger AB, Groot JFD. Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab. Journal of Clinical Oncology. 38: 2559-2559. DOI: 10.1200/Jco.2020.38.15_Suppl.2559  0.347
2020 Yuan Y, Lin R, Li D, Nie L, Warren K. Abstract A21: Time-to-event Bayesian optimal interval design to accelerate phase I pediatric oncology trials Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-A21  0.428
2020 Zhou Y, Li R, Yan F, Lee JJ, Yuan Y. A Comparative Study of Bayesian Optimal Interval (BOIN) Design With Interval 3 + 3 (i3 + 3) Design for Phase I Oncology Dose-Finding Trials Statistics in Biopharmaceutical Research. 1-9. DOI: 10.1080/19466315.2020.1811147  0.396
2019 Zhou Y, Lee JJ, Yuan Y. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Statistics in Medicine. PMID 31621952 DOI: 10.1002/Sim.8361  0.408
2019 Tidwell RSS, Peng SA, Chen M, Liu DD, Yuan Y, Lee JJ. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clinical Trials (London, England). 1740774519871471. PMID 31450957 DOI: 10.1177/1740774519871471  0.349
2019 Lin R, Thall PF, Yuan Y. An Adaptive Trial Design to Optimize Dose--Schedule Regimes with Delayed Outcomes. Biometrics. PMID 31273750 DOI: 10.1111/Biom.13116  0.426
2019 Lin R, Yuan Y. On the relative efficiency of model-assisted designs: a conditional approach. Journal of Biopharmaceutical Statistics. 1-15. PMID 31258039 DOI: 10.1080/10543406.2019.1632881  0.409
2019 Lin R, Yuan Y. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics (Oxford, England). PMID 30984972 DOI: 10.1093/Biostatistics/Kxz007  0.441
2019 Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. European Journal of Cancer (Oxford, England : 1990). 112: 83-93. PMID 30951926 DOI: 10.1016/J.Ejca.2019.02.007  0.345
2019 Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. Journal of the National Cancer Institute. PMID 30924863 DOI: 10.1093/Jnci/Djz049  0.383
2019 Wu J, Yuan Y, Cordova C, Aboud O, Penas-Prado M, Theeler BJ, Bryla C, Su Y, Grajkowska E, McCoy A, Boris L, Siegel C, Antony R, Garren N, Lawhon T, et al. Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults. Journal of Clinical Oncology. 37: 2031-2031. DOI: 10.1200/Jco.2019.37.15_Suppl.2031  0.367
2019 Wages NA, Yuan Y. Preface to the themed issue on ‘Early phase clinical trial design methodology’ Journal of the Royal Statistical Society Series C-Applied Statistics. 68: 267-269. DOI: 10.1111/Rssc.12329  0.354
2019 Yust-Katz S, Donthireddy V, Mandel J, Abunafeesa H, Patil N, Yadav D, Jabbour-Aida H, Wu J, Yuan Y, Tsavachidis S, Walbert T, Bondy M, Armstrong T. QOLP-30. CLINICAL PREDICTIVE MODEL FOR THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN GLIOBLASTOMA Neuro-Oncology. 21: vi204-vi204. DOI: 10.1093/Neuonc/Noz175.850  0.311
2019 Wu J, Bryla C, Su Y, Grajkowska E, McCoy A, Boris L, Antony R, Garren N, Siegel C, Cordova C, Aboud O, Vera E, Lawhon T, Penas-Prado M, Theeler B, ... ... Yuan Y, et al. ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS Neuro-Oncology. 21: vi27-vi28. DOI: 10.1093/Neuonc/Noz175.104  0.356
2019 Gross N, Ferrarotto R, Nagarajan P, Bell D, El-Naggar A, Johnson J, Yuan Y, Glisson B, Wong M, Rosenthal D, Esmaeli B, Migden M, Wargo J, Weber R, Myers J. Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN) Annals of Oncology. 30: v910. DOI: 10.1093/Annonc/Mdz394.071  0.316
2018 Liu S, Guo B, Yuan Y. A Bayesian Phase I/II Trial Design for Immunotherapy. Journal of the American Statistical Association. 113: 1016-1027. PMID 31741544 DOI: 10.1080/01621459.2017.1383260  0.43
2018 Murray TA, Yuan Y, Thall PF. A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes. Journal of the American Statistical Association. 113: 1255-1267. PMID 30739965 DOI: 10.1080/01621459.2017.1340887  0.301
2018 Tang R, Shen J, Yuan Y. ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage. Statistics in Medicine. PMID 30419609 DOI: 10.1002/Sim.8026  0.356
2018 Bahig H, Yuan Y, Mohamed ASR, Brock KK, Ng SP, Wang J, Ding Y, Hutcheson K, McCulloch M, Balter PA, Lai SY, Al-Mamgani A, Sonke JJ, van der Heide UA, Nutting C, et al. Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology. 13: 19-23. PMID 30386824 DOI: 10.1016/J.Ctro.2018.08.003  0.515
2018 Zhou H, Yuan Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Designs-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 5483-5484. PMID 30385656 DOI: 10.1158/1078-0432.Ccr-18-2677  0.358
2018 Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, et al. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. Bmc Cancer. 18: 903. PMID 30231854 DOI: 10.1186/S12885-018-4808-5  0.448
2018 Guo B, Li D, Yuan Y. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials. Pharmaceutical Statistics. PMID 29882388 DOI: 10.1002/Pst.1869  0.419
2018 Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, et al. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology. PMID 29788429 DOI: 10.1093/Neuonc/Noy056  0.314
2018 Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29769209 DOI: 10.1158/1078-0432.Ccr-18-0246  0.429
2018 Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Statistics in Medicine. PMID 29682777 DOI: 10.1002/Sim.7674  0.68
2018 Zhou H, Yuan Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29661774 DOI: 10.1158/1078-0432.Ccr-18-0168  0.446
2018 Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. Bmc Medical Research Methodology. 18: 32. PMID 29580203 DOI: 10.1186/S12874-018-0473-2  0.605
2018 Chu Y, Yuan Y. A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clinical Trials (London, England). 1740774518755122. PMID 29499621 DOI: 10.1177/1740774518755122  0.378
2018 Murray TA, Yuan Y, Thall PF, Elizondo JH, Hofstetter WL. A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics. PMID 29359314 DOI: 10.1111/Biom.12842  0.405
2018 Msaouel P, Thall PF, Yuan Y, Chen I, Tannir NM. A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps708  0.335
2018 Ursino M, Yuan Y, Alberti C, Comets E, Favrais G, Friede T, Lentz F, Stallard N, Zohar S. A dose finding design for seizure reduction in neonates Journal of the Royal Statistical Society: Series C (Applied Statistics). 68: 427-444. DOI: 10.1111/Rssc.12289  0.393
2018 Mu R, Yuan Y, Xu J, Mandrekar SJ, Yin J. gBOIN: a unified model‐assisted phase I trial design accounting for toxicity grades, and binary or continuous end points Journal of the Royal Statistical Society: Series C (Applied Statistics). 68: 289-308. DOI: 10.1111/Rssc.12263  0.406
2018 Chu Y, Yuan Y. BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity Journal of the Royal Statistical Society Series C-Applied Statistics. 67: 723-740. DOI: 10.1111/Rssc.12255  0.363
2018 Armstrong T, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Gilbert M. RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB Neuro-Oncology. 20: vi241-vi241. DOI: 10.1093/Neuonc/Noy148.998  0.323
2018 Puduvalli V, Wu J, Yuan Y, Armstrong T, Wu J, Giglio P, Xu J, Colman H, Walbert T, Raizer J, Groves M, Iwamoto F, Tran D, Avgeropoulos N, Paleologos N, et al. ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS Neuro-Oncology. 20: vi13-vi13. DOI: 10.1093/Neuonc/Noy148.047  0.315
2018 de Groot J, Penas-Prado M, Mandel J, O’Brien B, Weathers S, Loghin M, Kamiya-Matsuoka C, Zhou S, Colen R, Hunter K, Fuller G, Huse JT, Rao G, Weinberg J, Prabhu S, ... ... Yuan Y, et al. ATIM-07. WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS Neuro-Oncology. 20: vi2-vi2. DOI: 10.1093/Neuonc/Noy148.004  0.327
2017 Guo B, Yuan Y. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Journal of the American Statistical Association. 112: 508-520. PMID 32863478 DOI: 10.1080/01621459.2016.1228534  0.377
2017 Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y. Phase I-II clinical trial design: A state-of-the-art paradigm for dose finding. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29267863 DOI: 10.1093/Annonc/Mdx795  0.381
2017 Pan H, Yuan Y, Xia J. A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. Journal of the Royal Statistical Society. Series C, Applied Statistics. 66: 979-996. PMID 29249839 DOI: 10.1111/Rssc.12204  0.652
2017 Cai C, Rahbar MH, Hossain MM, Yuan Y, Gonzales NR. A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research. Contemporary Clinical Trials Communications. 7: 11-17. PMID 29062975 DOI: 10.1016/J.Conctc.2017.05.002  0.391
2017 Mandel JJ, Yust-Katz S, Patel AJ, Cachia D, Liu D, Park M, Yuan Y, A Kent T, de Groot JF. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro-Oncology. PMID 29016865 DOI: 10.1093/Neuonc/Nox144  0.343
2017 Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. Journal of the American Statistical Association. 112: 11-23. PMID 28943681 DOI: 10.1080/01621459.2016.1176926  0.37
2017 Shen W, Ning J, Yuan Y, Lok AS, Feng Z. Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics. PMID 28742219 DOI: 10.1111/Biom.12750  0.303
2017 Ahn J, Morita S, Wang W, Yuan Y. Bayesian analysis of longitudinal dyadic data with informative missing data using a dyadic shared-parameter model. Statistical Methods in Medical Research. 962280217715051. PMID 28629259 DOI: 10.1177/0962280217715051  0.326
2017 Zhou H, Lee JJ, Yuan Y. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Statistics in Medicine. PMID 28589563 DOI: 10.1002/Sim.7338  0.373
2017 Yan F, Mandrekar SJ, Yuan Y. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28546227 DOI: 10.1158/1078-0432.Ccr-17-0220  0.402
2017 Chen Z, Li Z, Zhuang R, Yuan Y, Kutner M, Owonikoko T, Curran WJ, Kowalski J. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile. Plos One. 12: e0170187. PMID 28125617 DOI: 10.1371/Journal.Pone.0170187  0.389
2017 Wu J, Bryla C, McCoy A, Lisa B, Garren N, Siegel C, Grajkowska E, Theeler B, Park DM, Parrott T, Armstrong TS, Yuan Y, Gilbert MR. ACTR-69. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR ADULTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA AND GLIOBLASTOMA Neuro-Oncology. 19: vi15-vi15. DOI: 10.1093/Neuonc/Nox168.056  0.349
2016 Zang Y, Yuan Y. Optimal sequential enrichment designs for phase II clinical trials. Statistics in Medicine. PMID 27640874 DOI: 10.1002/Sim.7128  0.383
2016 Zhang L, Yuan Y. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials. Statistics in Medicine. PMID 27580928 DOI: 10.1002/Sim.7095  0.42
2016 Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27407096 DOI: 10.1158/1078-0432.Ccr-16-0592  0.357
2016 Murray TA, Thall PF, Yuan Y. Utility-based designs for randomized comparative trials with categorical outcomes. Statistics in Medicine. PMID 27189672 DOI: 10.1002/Sim.6989  0.373
2016 Yuan Y, Guo B, Munsell M, Lu K, Jazaeri A. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Statistics in Medicine. PMID 27112322 DOI: 10.1002/Sim.6971  0.382
2016 Iasonos A, Wages NA, Conaway MR, Cheung K, Yuan Y, O'Quigley J. Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. Statistics in Medicine. PMID 27090197 DOI: 10.1002/Sim.6966  0.332
2016 Yuan Y, Liu Y, Li B, Wang B, Wang S, Peng Y. Short-chain fatty acids production and microbial community in sludge alkaline fermentation: Long-term effect of temperature. Bioresource Technology. 211: 685-690. PMID 27060243 DOI: 10.1016/J.Biortech.2016.03.138  0.432
2016 Chu Y, Pan H, Yuan Y. Adaptive dose modification for phase I clinical trials. Statistics in Medicine. PMID 27027650 DOI: 10.1002/Sim.6933  0.654
2016 Pan H, Yuan Y. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Statistics in Medicine. PMID 26991076 DOI: 10.1002/Sim.6941  0.666
2016 Riviere MK, Yuan Y, Jourdan JH, Dubois F, Zohar S. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. Statistical Methods in Medical Research. PMID 26988926 DOI: 10.1177/0962280216631763  0.415
2016 Zang Y, Liu S, Yuan Y. Optimal marker-strategy clinical trial design to detect predictive markers for targeted therapy. Biostatistics (Oxford, England). PMID 26951724 DOI: 10.1093/Biostatistics/Kxw006  0.345
2016 Guo B, Li Y, Yuan Y. A dose-schedule finding design for phase I-II clinical trials. Journal of the Royal Statistical Society. Series C, Applied Statistics. 65: 259-272. PMID 26877554 DOI: 10.1111/Rssc.12113  0.425
2016 Zhou R, Scheurer ME, Gilbert MR, Bondy M, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Brachman D, Bearden J, McGovern SL, Wilson SS, Judy KD, Robins HI, et al. Polymorphisms risk modeling for vascular toxicity in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Journal of Clinical Oncology. 34: 2049-2049. DOI: 10.1200/Jco.2016.34.15_Suppl.2049  0.318
2016 Zang Y, Lee JJ, Yuan Y. Two-stage marker-stratified clinical trial design in the presence of biomarker misclassification Journal of the Royal Statistical Society Series C-Applied Statistics. 65: 585-601. DOI: 10.1111/Rssc.12140  0.343
2016 Yuan X, Ji B, Yuan Y, Wu X, Zhang X. Co-scheduling of lock and water-land transshipment for ships passing the dam Applied Soft Computing Journal. 45: 150-162. DOI: 10.1016/j.asoc.2016.04.019  0.385
2015 Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, et al. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. Journal of Neuro-Oncology. PMID 26476729 DOI: 10.1007/S11060-015-1958-Z  0.325
2015 Chen Z, Yuan Y, Li Z, Kutner M, Owonikoko T, Curran WJ, Khuri F, Kowalski J. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials. Contemporary Clinical Trials. 43: 133-41. PMID 26012358 DOI: 10.1016/J.Cct.2015.05.014  0.433
2015 DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, Yuan Y, Liu D, Goldman S, Fisher P, Rytting M, Bouffet E, Khakoo Y, Hwang EI, Foreman N, et al. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). Journal of Neuro-Oncology. 123: 85-91. PMID 25859842 DOI: 10.1007/S11060-015-1764-7  0.331
2015 Shen W, Ning J, Yuan Y. A direct method to evaluate the time-dependent predictive accuracy for biomarkers. Biometrics. 71: 439-49. PMID 25758584 DOI: 10.1111/Biom.12293  0.315
2015 Shen W, Ning J, Yuan Y. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance. Statistics in Medicine. 34: 2104-15. PMID 25756852 DOI: 10.1002/Sim.6474  0.411
2015 Jin IH, Huo L, Yin G, Yuan Y. Phase I trial design for drug combinations with Bayesian model averaging. Pharmaceutical Statistics. 14: 108-19. PMID 25641851 DOI: 10.1002/Pst.1668  0.431
2015 Guo B, Yuan Y. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts. Statistics in Medicine. 34: 1721-32. PMID 25626676 DOI: 10.1002/Sim.6443  0.445
2015 Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Statistics in Medicine. 34: 1681-94. PMID 25626429 DOI: 10.1002/Sim.6442  0.669
2015 Guo B, Zang Y, Yuan Y. A Bayesian phase I/II clinical trial design in the presence of informative dropouts Statistics and Its Interface. 8: 217-226. DOI: 10.4310/Sii.2015.V8.N2.A9  0.348
2015 Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Groves MD, Raizer JJ, Giglio P, Colman H, Peereboom DM, Walbert T, Avgeropoulos NG, Iwamoto FM, Chamberlain MC, Paleologos N, Fink KL, et al. Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102). Journal of Clinical Oncology. 33: 2012-2012. DOI: 10.1200/Jco.2015.33.15_Suppl.2012  0.339
2015 Fellman BM, Yuan Y. Bayesian optimal interval design for phase I oncology clinical trials Stata Journal. 15: 110-120. DOI: 10.1177/1536867X1501500107  0.415
2015 Zang Y, Liu S, Yuan Y. Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers Journal of the Royal Statistical Society. Series C: Applied Statistics. 64: 635-650. DOI: 10.1111/Rssc.12092  0.38
2015 Liu S, Yuan Y. Bayesian optimal interval designs for phase I clinical trials Journal of the Royal Statistical Society Series C-Applied Statistics. 64: 507-523. DOI: 10.1111/Rssc.12089  0.44
2015 Riviere M-, Yuan Y, Dubois F, Zohar S. A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent Journal of the Royal Statistical Society Series C-Applied Statistics. 64: 215-229. DOI: 10.1111/Rssc.12072  0.428
2015 Zhou R, Scheurer M, Gilbert M, Bondy M, Sulman E, Yuan Y, Liu Y, Vera-Bolanos E, Wendland M, Brachman D, Bearden J, McGovern S, Wilson S, Judy K, Robins HI, et al. EPID-33RISK MODELING FOR VASCULAR TOXICITY IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825 Neuro-Oncology. 17: v85.3-v85. DOI: 10.1093/Neuonc/Nov213.33  0.323
2015 Scheurer ME, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera-Bolanos E, Wendland MM, Brachman DG, Stieber VW, Komaki RR, Flickinger JC, Kenyon LC, Robins HI, et al. EPID-25GERMLINE POLYMORPHISMS IN MGMT INCREASE ABILITY TO MODEL TEMOZOLOMIDE (TMZ)-RELATED MYELOTOXICITY RISK IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825 Neuro-Oncology. 17: v83.3-v83. DOI: 10.1093/Neuonc/Nov213.25  0.324
2015 Wu J, Puduvalli VK, Yuan Y, Armstrong T, Walker B, Upshaw C, Giglio P, Colman H, Groves MD, Raizer J, Walbert T, Tran D, Avgeropoulos N, Iwamoto F, Peereboom D, et al. ATCT-34BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB PLUS VORINOSTAT VERSUS BEVACIZUMAB ALONE IN ADULTS WITH RECURRENT GLIOBLASTOMA Neuro-Oncology. 17: v9.2-v9. DOI: 10.1093/Neuonc/Nov206.34  0.353
2014 Jin IH, Liu S, Thall PF, Yuan Y. Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. Journal of the American Statistical Association. 109: 525-536. PMID 25382884 DOI: 10.1080/01621459.2014.881740  0.391
2014 Pan H, Zhu C, Zhang F, Yuan Y, Zhang S, Zhang W, Li C, Wang L, Xia J. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach. Plos One. 9: e98147. PMID 24875783 DOI: 10.1371/Journal.Pone.0098147  0.641
2014 Zang Y, Lee JJ, Yuan Y. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clinical Trials (London, England). 11: 319-327. PMID 24844841 DOI: 10.1177/1740774514529848  0.399
2014 Riviere MK, Yuan Y, Dubois F, Zohar S. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. Pharmaceutical Statistics. 13: 247-57. PMID 24828456 DOI: 10.1002/Pst.1621  0.429
2014 Cai C, Liu S, Yuan Y. A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Statistics in Medicine. 33: 4017-28. PMID 24817556 DOI: 10.1002/Sim.6200  0.391
2014 Cai C, Yuan Y, Ji Y. A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents. Journal of the Royal Statistical Society. Series C, Applied Statistics. 63: 159-173. PMID 24511160 DOI: 10.1111/Rssc.12039  0.385
2014 Yuan Y, Mackinnon DP. Robust mediation analysis based on median regression. Psychological Methods. 19: 1-20. PMID 24079925 DOI: 10.1037/A0033820  0.302
2014 Armstrong TS, Vera-Bolanos E, Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Mendoza T. At-07A Phase Ii Study Of Lapatinib And Dose-Dense Temozolomide (Tmz) For Adults With Recurrent Ependymoma: Patient Reported Outcomes (Pro) From A Cern Clinical Trial. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.7  0.33
2014 Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Armstrong T, Aldape K. AT-23 * A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL Neuro-Oncology. 16: v13-v13. DOI: 10.1093/Neuonc/Nou237.23  0.367
2013 Liu S, Yin G, Yuan Y. BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY. The Annals of Applied Statistics. 7: 1837-2457. PMID 24707327 DOI: 10.1214/13-Aoas661  0.428
2013 Ahn J, Liu S, Wang W, Yuan Y. Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts. Biometrics. 69: 914-24. PMID 24328715 DOI: 10.1111/Biom.12100  0.336
2013 Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer. 119: 2747-53. PMID 23633392 DOI: 10.1002/Cncr.28031  0.363
2013 Cai C, Yuan Y, Johnson VE. Bayesian adaptive phase II screening design for combination trials. Clinical Trials (London, England). 10: 353-62. PMID 23359875 DOI: 10.1177/1740774512470316  0.366
2012 Huo L, Yuan Y, Yin G. Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses. Bayesian Analysis (Online). 7: 1035-1052. PMID 23956811 DOI: 10.1214/12-Ba735  0.396
2012 Zhang G, Yuan Y. BAYESIAN MODELING LONGITUDINAL DYADIC DATA WITH NONIGNORABLE DROPOUT, WITH APPLICATION TO A BREAST CANCER STUDY. The Annals of Applied Statistics. 6: 753-771. PMID 23814631 DOI: 10.1214/11-Aoas515  0.51
2011 Yuan Y, Yin G. BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS. The Annals of Applied Statistics. 5: 924-942. PMID 22375162 DOI: 10.1214/10-Aoas433  0.422
2011 Yuan Y, Yin G. Robust EM Continual Reassessment Method in Oncology Dose Finding. Journal of the American Statistical Association. 106: 818-831. PMID 22375092 DOI: 10.1198/Jasa.2011.Ap09476  0.43
2011 Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Statistics in Medicine. 30: 1218-29. PMID 21432894 DOI: 10.1002/Sim.4218  0.38
2011 Yuan Y, Yin G. Bayesian hybrid dose-finding design in phase I oncology clinical trials. Statistics in Medicine. 30: 2098-108. PMID 21365672 DOI: 10.1002/Sim.4164  0.407
2011 Lei X, Yuan Y, Yin G. Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity. Lifetime Data Analysis. 17: 156-74. PMID 20364321 DOI: 10.1007/S10985-010-9163-Z  0.422
2010 Yuan Y, Yin G. Bayesian quantile regression for longitudinal studies with nonignorable missing data. Biometrics. 66: 105-14. PMID 19459836 DOI: 10.1111/J.1541-0420.2009.01269.X  0.327
2009 Yin G, Yuan Y. A latent contingency table approach to dose finding for combinations of two agents. Biometrics. 65: 866-75. PMID 18759848 DOI: 10.1111/J.1541-0420.2008.01119.X  0.421
2009 Yuan Y, Little RJ. Mixed-effect hybrid models for longitudinal data with nonignorable dropout. Biometrics. 65: 478-86. PMID 18759842 DOI: 10.1111/J.1541-0420.2008.01102.X  0.59
2009 Yuan Y, Little RJ. Meta-analysis of studies with missing data. Biometrics. 65: 487-96. PMID 18565168 DOI: 10.1111/J.1541-0420.2008.01068.X  0.612
2009 Song PX, Li M, Yuan Y. Joint regression analysis of correlated data using Gaussian copulas. Biometrics. 65: 60-8. PMID 18510653 DOI: 10.1111/J.1541-0420.2008.01058.X  0.3
2009 Yin G, Yuan Y. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials Journal of the American Statistical Association. 104: 954-968. DOI: 10.1198/Jasa.2009.Ap08425  0.44
2009 Yuan Y, Yin G. Bayesian dose finding by jointly modelling toxicity and efficacy as time-to-event outcomes Journal of the Royal Statistical Society: Series C (Applied Statistics). 58: 719-736. DOI: 10.1111/J.1467-9876.2009.00674.X  0.433
2009 Yin G, Yuan Y. Bayesian dose finding in oncology for drug combinations by copula regression Journal of the Royal Statistical Society: Series C (Applied Statistics). 58: 211-224. DOI: 10.1111/J.1467-9876.2009.00649.X  0.408
2008 Yuan Y, Yin G. Sequential continual reassessment method for two-dimensional dose finding. Statistics in Medicine. 27: 5664-78. PMID 18618901 DOI: 10.1002/Sim.3372  0.4
2007 Yuan Y, Little RJ. Parametric and semiparametric model-based estimates of the finite population mean for two-stage cluster samples with item nonresponse. Biometrics. 63: 1172-80. PMID 17489967 DOI: 10.1111/J.1541-0420.2007.00816.X  0.587
Show low-probability matches.